A
원바이오젠
307280KOSDAQ73.8 / 100
Reference Date: 2026-09-08
Financial Score33.5 / 40
News Sentiment21.3 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Rose 7.1% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Wonbiogen is a wound care dressing manufacturer specializing in foam and hydrocolloid dressings, supplying hospitals, pharmacies, and OTC markets. Market growth is driven by expanded health insurance coverage, aging population, changing perceptions of wound care, and increasing demand for aesthetic purposes.
Number of Employees
77people
Average Salary
0.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
6.29Industry Average 15.008.0Point
Half of industry avg (excellent)
PBR
0.98Industry Average 1.204.0Point
In line with industry avg
ROE
16.17Industry Average 8.007.0Point
2.0x industry avg (excellent)
Debt Ratio
1.15Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲9.3% (2-year basis)
Operating Profit Growth Rate
2.0 / 3
Avg ▲6.8% (2-year basis)
ROE Trend
2.5 / 4
Avg ROE 17.2% (declining, 3yr)
Detailed News Sentiment
1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85
- Positive원바이오젠, 상반기 영업이익 49억원 달성… 전년비 43.0%↑
원바이오젠의 상반기 영업이익이 전년 대비 43% 증가하며 성장을 이어갔다.
Detailed Momentum
52-week position3.0Point
52w lower range (29%)
Current 5,870Won52-week high 8,25052-week low 4,875
1-month return5.0Point
1m +7.12% (rising)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral반기보고서 (2026.06)2026-08-14